Tech Stock Options Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Tech Stock Options

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Michael Rich who wrote (28740)	11/18/1997 3:23:00 PM
From: j g cordes	Read Replies (1) of 58727

Michael, CHIR is dropping, drooping.. whatever, its falling towards its long term support trend. There's an interesting blurb which supports my optimism for a nice trade here (or lower.. even to 16?) from M Murphy... though he's had his head handed to him more than once. Anyway I've quoted it below if you have anything to add from your resources. "To: Celeryroot (945 ) From: G-MAN Saturday, Nov 15 1997 1:39PM EST Reply #946 of 947 To All: Michael Murphy, editor of the California Technology Stock Letter, seems to think that Cephalon and Chiron will get approval for Myotrophin by year end or early 1998. He thinks that Wall Street is discounting the shares of Chiron for the simple reason that the drug will be ultimately denied approval. It will be interesting to see what happens to the shares if the drug is approved. (Maybe an investment in Cephalon calls with a Feb to April expiration date may be an interesting gamble.) I'm sure that most everyone here either gets the CTSL or the Medical Technology Stock Letter. Both Murphy and McCamant are table thumpers regarding Chiron for the long term. Regarding the short term, one has to just wait it out."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next